Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects With Primary Hyperlipidemia or Mixed Dyslipidemia At Risk Of Cardiovascular Events

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 746 participants.

Also called NCT02100514

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 746 participants (enrolled count) (from the registry)
Sponsor
  • Pfizer Registry lists this organization as the lead sponsor
Registry
  • NCT NCT02100514
  • EudraCT 2014-000478-20
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Canada, Czechia, Finland, Netherlands, Norway, Poland, Puerto Rico, Singapore, South Korea, Sweden, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02100514. Randomized; triple masking; primary purpose treatment. Start 2014-10-28 (actual); primary completion 2016-07-15 (actual). Results posted on 2017-07-21.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects With Primary Hyperlipidemia or Mixed Dyslipidemia At Risk Of Cardiovascular Events
Acronym
SPIRE-LL
Condition
Hyperlipidemia
Intervention (Drug)
Bococizumab (PF-04950615; RN316)
Intervention (Other)
Placebo
Lead sponsor
Pfizer (class: industry)

Record details

Record id
cardio:ct-nct02100514
Content hash
29794032b6fcbc25edece739cb7152992021baba9ac5ba8e25c516b745acf957